Here, we describe three examples of in vivo base editing using either cytosine or adenine base editors to correct mutations that cause (5.1) Duchenne muscular dystrophy (Dmd); (5.2) phenylketonuria (PKU); or (5.3) hereditary tyrosinemia type I (HTI) in mouse models. This evidence concerns the gene DMD and Duchenne muscular dystrophy.